Literature DB >> 22236140

Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.

S D Hafeman1, D Varland, S W Dow.   

Abstract

Canine malignant histiocytosis (MH) is an aggressive neoplasm of macrophages and dendritic cells. It carries a poor prognosis because of the development of widespread metastasis and poor sensitivity to chemotherapy. Thus, there is a large need for new treatments for MH. We hypothesized that bisphosphonates might be useful to increase the effectiveness of cytotoxic chemotherapy against MH. To address this question, we conducted in vitro screening studies using MH cell lines and a panel of 6 chemotherapy and 5 bisphosphonate drugs. The combination of clodronate with vincristine was found to elicit synergistic killing which was associated with a significant increase in cell cycle arrest. Second, zoledronate combined with doxorubicin also significantly increased cell killing. Zoledronate significantly increased the uptake of doxorubicin by MH cells. On the basis of these findings, we conclude that certain bisphosphonate drugs may increase the overall effectiveness of chemotherapy for MH in dogs.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22236140      PMCID: PMC3278520          DOI: 10.1111/j.1476-5829.2011.00274.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  63 in total

1.  Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model.

Authors:  F Alves-Rosa; C Stanganelli; J Cabrera; N van Rooijen; M S Palermo; M A Isturiz
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters.

Authors:  D L Gustafson; D H Thamm
Journal:  J Vet Intern Med       Date:  2010-03-22       Impact factor: 3.333

3.  Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs.

Authors:  Regina Zavodovskaya; Albert T Liao; Cameron L R Jones; Becky Yip; May B Chien; Peter F Moore; Cheryl A London
Journal:  Am J Vet Res       Date:  2006-04       Impact factor: 1.156

4.  A macrophage-monocyte cell line from a dog with malignant histiocytosis.

Authors:  M L Wellman; S Krakowka; R M Jacobs; G J Kociba
Journal:  In Vitro Cell Dev Biol       Date:  1988-03

5.  Bone metabolic effects of single-dose zoledronate in healthy dogs.

Authors:  Louis-Philippe de Lorimier; Timothy M Fan
Journal:  J Vet Intern Med       Date:  2005 Nov-Dec       Impact factor: 3.333

6.  CCNU for the treatment of dogs with histiocytic sarcoma.

Authors:  Katherine A Skorupski; Craig A Clifford; Melissa C Paoloni; Ana Lara-Garcia; Lisa Barber; Michael S Kent; Amy K LeBlanc; Aarti Sabhlok; Elizabeth A Mauldin; Frances S Shofer; C Guillermo Couto; Karin U Sørenmo
Journal:  J Vet Intern Med       Date:  2007 Jan-Feb       Impact factor: 3.333

Review 7.  In vitro and in vivo antitumor effects of bisphosphonates.

Authors:  Philippe Clézardin; Pierrick Fournier; Sandrine Boissier; Olivier Peyruchaud
Journal:  Curr Med Chem       Date:  2003-01       Impact factor: 4.530

8.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

9.  Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma.

Authors:  Nathan R Miselis; Zhijin J Wu; Nico Van Rooijen; Agnes B Kane
Journal:  Mol Cancer Ther       Date:  2008-03-28       Impact factor: 6.261

10.  Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages.

Authors:  M G Cecchini; R Felix; H Fleisch; P H Cooper
Journal:  J Bone Miner Res       Date:  1987-04       Impact factor: 6.741

View more
  10 in total

1.  Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.

Authors:  Nicole M Reusser; Heather J Dalton; Sunila Pradeep; Vianey Gonzalez-Villasana; Nicholas B Jennings; Hernan G Vasquez; Yunfei Wen; Rajesh Rupaimoole; Archana S Nagaraja; Kshipra Gharpure; Takahito Miyake; Jie Huang; Wei Hu; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

2.  Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.

Authors:  Sicheng Lu; Mengjie Guo; Zhimin Fan; Ying Chen; Xuqin Shi; Chunyan Gu; Ye Yang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

3.  Genome-wide DNA copy number analysis and targeted transcriptional analysis of canine histiocytic malignancies identifies diagnostic signatures and highlights disruption of spindle assembly complex.

Authors:  Katherine Kennedy; Rachael Thomas; Jessica Durrant; Tao Jiang; Alison Motsinger-Reif; Matthew Breen
Journal:  Chromosome Res       Date:  2019-04-23       Impact factor: 5.239

4.  The Electroporation as a Tool for Studying the Role of Plasma Membrane in the Mechanism of Cytotoxicity of Bisphosphonates and Menadione.

Authors:  Mantas Šilkūnas; Rita Saulė; Danutė Batiuškaitė; Gintautas Saulis
Journal:  J Membr Biol       Date:  2016-04-04       Impact factor: 1.843

5.  Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.

Authors:  Hajime Asada; Hirotaka Tomiyasu; Yuko Goto-Koshino; Yasuhito Fujino; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2015-02-21       Impact factor: 1.267

6.  Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.

Authors:  Marwan Ibrahim Abdullah; Mohammed Najim Abed; Alan Richardson
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

7.  A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.

Authors:  Marilia Takada; Maciej Parys; Emmalena Gregory-Bryson; Paulo Vilar Saavedra; Matti Kiupel; Vilma Yuzbasiyan-Gurkan
Journal:  BMC Cancer       Date:  2018-03-01       Impact factor: 4.430

8.  Synergistic Antitumor Interaction of Risedronate Sodium and Standard Anticancer Agents in Canine (D-17) and Human Osteosarcoma (U-2 OS) Cell Lines.

Authors:  Dominik Poradowski; Aleksander Chrószcz; Bożena Obmińska-Mrukowicz
Journal:  Animals (Basel)       Date:  2022-03-29       Impact factor: 2.752

9.  Lymph Node Abscessation Secondary to Neoplasia in Two Dogs.

Authors:  Erin Close; Sarah Lumbrezer-Johnson; Eric Hostnik; Rhonda Burge; Ryan Jennings; Laura Selmic
Journal:  Case Rep Vet Med       Date:  2022-03-26

Review 10.  Canine Histiocytic Malignancies-Challenges and Opportunities.

Authors:  Katherine Kennedy; Rachael Thomas; Matthew Breen
Journal:  Vet Sci       Date:  2016-01-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.